2023-506396-94-00
Completed
Phase 1
A first-in-human phase 1, single center, randomized, double-blind, placebo-controlled study to evaluate the safety and immunogenicity of three dose levels of the OVX033 vaccine, after intramuscular administration in healthy subjects aged 18-49 years
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Osivax
- Enrollment
- 48
- Locations
- 1
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Florence Nicolas - Chief Development Officer
Scientific
Osivax
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Not specified
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 1
A randomized first-in-human, Phase 1, single-center, observer-blind, active-controlled 3-arm study to evaluate the safety, tolerability, and immunogenicity of one single administration of TETRALITE, a novel adjuvanted influenza vaccine, in healthy participants aged 18 to 50 years2022-500681-98-00Litevax B.V.60
Not yet recruiting
Not Applicable
A phase 1 clinical trial to evaluate safety, tolerability, pharmacokinetic properties and effectiveness after applying an investigational cream to healthy adults and atopic dermatitis patientsDiseases of the skin and subcutaneous tissueKCT0005182Avixgen24
Recruiting
Not Applicable
A Randomized, Observer-blind, First-in-Human Phase 1/2a Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Three Different Doses of VAC52416 (ExPEC10V) in Adults Aged 60 to 85 Years in Stable HealthNL-OMON52538Janssen-Cilag80
Active, not recruiting
Phase 1
A Study of Three Different Doses of VAC52416 (ExPEC10V) in Adults Aged 60 to 85 Years in Stable HealthHealthy volunteers (Prevention of invasive extraintestinal pathogenic Escherichia coli (ExPEC) disease)Therapeutic area: Diseases [C] - Bacterial Infections and Mycoses [C01]EUCTR2020-000657-27-FRJanssen Vaccines & Prevention B.V.1,004
Active, not recruiting
Phase 1
A Study of Three Different Doses of VAC52416 (ExPEC10V) in Adults Aged 60 to 85 Years in Stable HealthEUCTR2020-000657-27-NLJanssen Vaccines & Prevention B.V.1,004